INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics
INMB Price/Volume Stats
| Current price | $4.56 | 52-week high | $14.74 |
| Prev. close | $4.71 | 52-week low | $4.45 |
| Day low | $4.45 | Volume | 188,600 |
| Day high | $4.70 | Avg. volume | 165,735 |
| 50-day MA | $5.43 | Dividend yield | N/A |
| 200-day MA | $8.59 | Market Cap | 101.10M |
INMB Stock Price Chart Interactive Chart >
INmune Bio Inc. - Common stock (INMB) Company Bio
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
INMB Price Returns
| 1-mo | -11.28% |
| 3-mo | -34.39% |
| 6-mo | -54.90% |
| 1-year | -47.22% |
| 3-year | -63.26% |
| 5-year | 16.75% |
| YTD | -59.50% |
| 2023 | 77.60% |
| 2022 | -37.84% |
| 2021 | -40.77% |
| 2020 | 196.90% |
| 2019 | N/A |
Loading social stream, please wait...